Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Rigel Pharmaceuticals Q3 EPS $1.46 Beats $0.84 Estimate, Sales $69.462M Beat $61.880M Estimate

Author: Benzinga Newsdesk | November 04, 2025 04:03pm
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $0.84 by 73.19 percent. This is a 108.57 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $69.462 million which beat the analyst consensus estimate of $61.880 million by 12.25 percent. This is a 25.59 percent increase over sales of $55.307 million the same period last year.

Posted In: RIGL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist